Updates are available Correction dated 2026-01-21
Click to view Correction: https://doi.org/10.1038/s41531-026-01267-1
-
Authors
Boura, Iro
Sait, Shaimaa
Marinakis, Nikolaos M.
Arvind, Kumar
Chia, Ruth
Ray, Anindita
Vatsellas, Giannis
Loupis, Theodoros
Pavlaki, Vasiliki
Makrythanasis, Periklis
Mitsias, Panayiotis
Xiromerisiou, Georgia
Scholz, Sonja W.
Spanaki, Cleanthe
- License Information
-
More Information
Article History
Received: 29 August 2025
Accepted: 24 October 2025
First Online: 18 December 2025
Change Date: 21 January 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41531-026-01267-1
Competing interests
: I.B. has received research funding from the Project CHAngeing - Connected Hubs in Ageing: Healthy Living to Protect Cerebrovascular Function (grant agreement 101087071), funded by the European Union’s Horizon Europe Program (Excellence Hubs Call—Horizon-WIDERA-2022-ACCESS-04-01, and the European Union-NextGeneration EU (project code: TAEDR-0535850), as well as honoraria for educational and travel grants from AbbVie. P.MI. has received research funding from the Hellenic Precision Medicine Network, the European Union Horizon 2020 research innovation program under the Marie Sklodowska-Curie grant agreement No 101007926 and the European Union’s Horizon Europe Program (Excellence Hubs Call – Horizon-WIDERA-2022-ACCESS-04-01 under grant agreement No 101087071). G.X. has received honoraria for lecturing, advisory fees, educational grants, and travel grants from ITF Hellas, Innovis, AbbVie, and Teva. S.W.S. receives research support from Cerevel Therapeutics, she is a scientific advisory board member of the Lewy Body Dementia Association, Mission MSA, and the GBA1 Canada Initiative, and an editorial board member of JAMA Neurology and the Journal of Parkinson’s Disease. C.S. has received research funding from the Greek National Precision Medicine Network, the European Union’s Horizon 2020 research innovation program under the Marie Sklodowska-Curie grant agreement No 101007926, the European Union-NextGeneration EU (project code: TAEDR-0535850), and the European Union’s Horizon Europe Program (Excellence Hubs Call – Horizon-WIDERA-2022-ACCESS-04-01 under grant agreement No 101087071), as well as honoraria for lecturing, advisory fees, educational grants, and travel grants from ITF Hellas, Innovis, Merck Serono, AbbVie, CSL Behring, Roche and Teva. All other authors declare no financial or non-financial competing interests.
